KR20120077357A - Anti-inflammatory composition and anti-oxidative composition using an extract of teucrium veronicoides - Google Patents

Anti-inflammatory composition and anti-oxidative composition using an extract of teucrium veronicoides Download PDF

Info

Publication number
KR20120077357A
KR20120077357A KR1020100139290A KR20100139290A KR20120077357A KR 20120077357 A KR20120077357 A KR 20120077357A KR 1020100139290 A KR1020100139290 A KR 1020100139290A KR 20100139290 A KR20100139290 A KR 20100139290A KR 20120077357 A KR20120077357 A KR 20120077357A
Authority
KR
South Korea
Prior art keywords
composition
inflammatory
extract
essential oil
present
Prior art date
Application number
KR1020100139290A
Other languages
Korean (ko)
Inventor
송민호
현창구
문영건
홍준석
이남호
Original Assignee
주식회사 해이래
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 해이래 filed Critical 주식회사 해이래
Priority to KR1020100139290A priority Critical patent/KR20120077357A/en
Publication of KR20120077357A publication Critical patent/KR20120077357A/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/532—Agastache, e.g. giant hyssop
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

PURPOSE: An anti-inflammatory and anti-oxidative composition containing Teucrium veronicoides essential oil extract is provided to suppress TNF-alpha and IL-8 generation and to remove DPPH radical. CONSTITUTION: An anti-inflammatory composition contains Teucrium veronicoides essential oil extract as an active ingredient. An antioxidative composition contains the extract as an active ingredient. The composition is a pharmaceutical, food, or cosmetic composition. The pharmaceutical composition is manufactured in the form of an oral formulation(tablet, suspension, granule, emulsion, capsule, syrup), parenteral formulation(aqueous or oil suspension for sterilization injection), topical formulation(solution, cream, ointment, gel, lotion, patch). The daily dosage of the pharmaceutical composition is 0.001-150 mg/kg.

Description

곽향 정유 추출물을 이용한 항염증제 조성물 및 항산화제 조성물{Anti-inflammatory Composition and Anti-oxidative Composition Using an Extract of Teucrium veronicoides}Anti-inflammatory Composition and Anti-oxidative Composition Using an Extract of Teucrium veronicoides

본 발명은 곽향(Teucrium veronicoides) 정유 추출물을 이용한 항염증제 조성물 및 항산화제 조성물에 관한 것이다.
The present invention relates to an anti-inflammatory composition and an antioxidant composition using Teucrium veronicoides essential oil extract.

염증은 외부의 물리?화학적 자극, 박테리아, 곰팡이, 바이러스, 각종 알레르기 유발 물질 등 외부 감염원의 감염에 대한 생체의 방어 반응이다. Inflammation is the body's defense against external infections such as physical and chemical stimuli, bacteria, fungi, viruses, and allergens.

염증 반응은 선천성 면역 반응의 일부이며, 다른 동물에서처럼 인간의 선천성 면역 반응은 대식세포가 병원체에 특이적으로 존재하는 세포 표면의 패턴을 통해 비자기(non-self)로 인식하고 공격함으로써 시작된다. 염증 반응 시에는 염증 부위에 혈장이 축적되어 세균이 분비한 독성을 희석시키며, 혈류가 증가하고, 홍반, 통증, 부종, 발열 등의 증상이 수반되게 된다.Inflammatory responses are part of the innate immune response, and as in other animals, the innate immune response in humans begins by recognizing and attacking non-self through patterns of cell surfaces where macrophages are specifically present in pathogens. During the inflammatory reaction, plasma accumulates at the site of inflammation, diluting the toxicity secreted by bacteria, increasing blood flow, and accompanied by symptoms such as erythema, pain, edema, and fever.

이러한 염증 반응에는 반응성 활성 산소종, 프로스타글란딘, 루코트리엔 등과 같은 염증 매개체, TNF-α, IL-6 및 IL-8 등과 같은 염증성 사이토카인 등이 관여하는 것으로 알려져 있다(J. Clin. Pathol. 54, pp.577-589, 2001; Eur. Heart J. 23, pp.345-0347, 2002). These inflammatory reactions are known to involve reactive reactive oxygen species, inflammatory mediators such as prostaglandins, leukotrienes and the like, and inflammatory cytokines such as TNF-α, IL-6, and IL-8 (J. Clin. Pathol. 54, pp. 577-589, 2001; Eur. Heart J. 23, pp. 345-0347, 2002).

TNF-α는 외부의 자극이나 LPS(lipopolysaccharide) 등 감염원에 의해 비만세포, 면역세포 등에서 분비되는 대표적인 사이토카인이다. 동물이나 인체에 투여했을 때, 염증, 발열, 출혈, 혈액 응고, 급성 감염이나 쇼크 상태에서 나타나는 반응과 유사한 급성 단계 반응 (acute phase response) 등을 유발하며, 심근경색, 발작, 순환계 쇼크 등의 매개자로서도 작용한다고 알려져 있다(AM. J. Path. 135(1), 121-132(1989)). 또한 건선, 습진, 지루성 피부염, 접촉성 피부염 등을 매개하는 것으로도 알려져 있다(Ann. Dermatol. Venereol. 129(12):1374-9, 2002).TNF-α is a representative cytokine secreted by mast cells and immune cells by external stimuli or infectious agents such as LPS (lipopolysaccharide). When administered to an animal or human body, it causes inflammation, fever, bleeding, blood clotting, acute phase responses similar to those seen in acute infections or shock conditions, and mediators such as myocardial infarction, seizures, and circulatory shock. It is also known to act as (AM. J. Path. 135 (1), 121-132 (1989)). It is also known to mediate psoriasis, eczema, seborrheic dermatitis and contact dermatitis (Ann. Dermatol. Venereol. 129 (12): 1374-9, 2002).

IL-8은 비만세포 등에서 IL-1α, IL-1β, TNF-α 등과 같은 염증성 사이토카인에 의하여 분비되어 광범위한 급성 및 만성 염증 반응을 매개하는데, 특히 아토피 피부염, 건선 등의 피부염, 관절염, 사구체 신염 등에 관련되어 있다.IL-8 is secreted by inflammatory cytokines such as IL-1α, IL-1β, and TNF-α in mast cells and mediates a wide range of acute and chronic inflammatory reactions.In particular, atopic dermatitis, psoriasis dermatitis, arthritis, glomerulonephritis And so on.

한편 인간의 질병, 노화 등은 체내 대사 과정 중 발생하는 활성산소종(일중항산소(singlet oxygen), 초과산화이온(superoxide anion), 수산화자유기, 과산화수소(hydrogen peroxide) 등)이 단백질, DNA 등을 손상시키는 산화 반응에 기인하는데(Mol. Cell Biochem., 111, pp109-115, 1992), 항산화란 이러한 산화 반응의 억제 활성을 말한다. 항산화 활성을 갖는 물질의 탐색에는 DPPH 라디칼 소거 활성, Superoxide Anion 라디칼 소거 활성, Xanthine oxidase 억제 활성 등이 이용되고 있다.On the other hand, human disease and aging include free radicals (singlet oxygen, superoxide anion, free radicals, hydrogen peroxide, etc.) that occur during metabolic processes in the body. (Mol. Cell Biochem., 111, pp 109-115, 1992). Antioxidant refers to the inhibitory activity of this oxidation reaction. DPPH radical scavenging activity, Superoxide Anion radical scavenging activity, Xanthine oxidase inhibitory activity, etc. are used for the search of the substance which has antioxidant activity.

본 발명은 곽향 정유 추출물의 항염증 활성과 항산화 활성을 개시한다.
The present invention discloses the anti-inflammatory activity and antioxidant activity of the essential oil extract.

본 발명의 목적은 항염증제 조성물과 항산화제 조성물을 제공하는 데 있다.It is an object of the present invention to provide an anti-inflammatory composition and an antioxidant composition.

본 발명의 구체적인 목적은 이하에서 제시될 것이다.
The specific object of the present invention will be presented below.

본 발명자들은 아래의 실시예 및 실험예에서 확인되는 바와 같이, 곽향 정유 추출물을 제조하고, 이 곽향 정유 추출물이 농도 의존적으로 LPS로 자극된 대식세포 계열의 THP-1 세포주의 TNF-α 및 IL-8의 생성을 억제하고, DPPH 라디칼의 소거 활성을 보임을 확인함으로써 완성된 것이다.The inventors of the present invention prepared the extract of the essential oil as confirmed in the following Examples and Experimental Examples, and the extract of the essential oil of TNF-α and IL- of THP-1 cell line of the macrophage-type THP-1 cell line stimulated concentration-dependently. It was completed by suppressing the production of 8 and showing scavenging activity of DPPH radicals.

본 발명은 이러한 실험 결과에 기초하여 제공되는 것으로서, 일 측면에 있어서본 발명은 곽향 정유 추출물을 유효성분으로 하는 항염증제 조성물로 파악할 수 있고, 다른 측면에 있어서는 곽향 정유 추출물을 유효성분으로 하는 항산화제 조성물로 파악할 수 있다.The present invention is provided based on the results of such experiments, in one aspect the present invention can be understood as an anti-inflammatory composition containing the essence essential oil extract as an active ingredient, and in another aspect an antioxidant composition as an active ingredient erectile essential oil extract You can figure it out.

본 명세서에서, 상기 "유효성분"의 의미는 단독으로 목적하는 활성을 나타내거나 또는 그 자체는 활성이 없는 담체와 함께 활성을 나타낼 수 있는 성분을 의미한다.In the present specification, the term "active ingredient" means a component that can exhibit activity alone or in combination with a carrier which is not active in itself.

또 본 명세서에서, "항염증"은 아래에서 정의되는 염증성 질환의 개선, 치료, 그러한 질환의 발병 억제 또는 지연을 포함하는 의미이다.In addition, in the present specification, "anti-inflammatory" is meant to include the improvement, treatment, inhibition or delay of the development of inflammatory diseases as defined below.

또 본 명세서에서, 상기 "염증성 질환"이란 외부의 물리?화학적 자극 또는 박테리아, 곰팡이, 바이러스, 각종 알레르기 유발 물질 등 외부 감염원의 감염에 대한 국부적 또는 전신적 생체 방어 반응으로 특정되는 어떠한 상태로서 정의될 있다. 이러한 반응은 각종 염증 매개 인자와 면역세포와 관련된 효소(예컨대 iNOS, COX-2 등) 활성화, 염증 매개 물질의 분비(예컨대, NO, TNF-α, IL-6, IL-1β, PGE2의 분비), 체액 침윤, 세포 이동, 조직 파괴 등의 일련의 복합적인 생리적 반응을 수반하며, 홍반, 통증, 부종, 발열, 신체의 특정 기능의 저하 또는 상실 등의 증상에 의해 외적으로 나타난다. 상기 염증성 질환은 급성, 만성, 궤양성, 알레르기성 또는 괴사성을 띨 수 있으므로, 어떠한 질환이 상기와 같은 염증성 질환의 정의에 포함되는 한 그것이 급성이든지, 만성이든지, 궤양성이든지, 알레르기성이든지 또는 괴사성이든지를 불문한다. 구체적으로 상기 염증성 질환에는 천식, 알레르기성 및 비-알레르기성 비염, 만성 및 급성 비염, 만성 및 급성 위염 또는 장염, 궤양성 위염, 급성 및 만성 신장염, 급성 및 만성 간염, 만성 폐쇄성 폐질환, 폐섬유증, 과민성 대장 증후군, 염증성 통증, 편두퐁, 두통, 허리 통증, 섬유 근육통, 근막 질환, 바이러스 감염(예컨대, C형 감염), 박테리아 감염, 곰팡이 감염, 화상, 외과적 또는 치과적 수술에 의한 상처, 프로스타글라딘 E 과다 증후군, 아테롬성 동맥 경화증, 통풍, 관절염, 류머티스성 관절염, 강직성 척추염, 호지킨병, 췌장염, 결막염, 홍채염, 공막염, 포도막염, 피부염(아토피성 피부염 포함), 습진, 다발성 경화증 등이 포함될 것이다. In addition, in the present specification, the "inflammatory disease" may be defined as any condition specified by a local or systemic biological defense response against external physical and chemical stimuli or infection of an external infectious agent such as bacteria, fungi, viruses, and various allergens. . This response activates various inflammatory mediators and enzymes associated with immune cells (eg iNOS, COX-2, etc.), secretion of inflammatory mediators (eg NO, TNF-α, IL-6, IL-1β, PGE 2) . ), Accompanied by a series of complex physiological reactions such as fluid infiltration, cell migration, tissue destruction, etc., and are manifested externally by symptoms such as erythema, pain, edema, fever, deterioration or loss of certain functions of the body. The inflammatory disease may be acute, chronic, ulcerative, allergic or necrotic, so as long as any disease is included in the definition of an inflammatory disease as above, whether it is acute, chronic, ulcerative, allergic or Irrespective of necrosis Specifically, the inflammatory diseases include asthma, allergic and non-allergic rhinitis, chronic and acute rhinitis, chronic and acute gastritis or enteritis, ulcerative gastritis, acute and chronic nephritis, acute and chronic hepatitis, chronic obstructive pulmonary disease, pulmonary fibrosis Irritable bowel syndrome, inflammatory pain, migraines, headache, back pain, fibromyalgia, fascia disease, viral infections (eg, type C infections), bacterial infections, fungal infections, burns, surgical or dental wounds, Prostaglandin E excess syndrome, atherosclerosis, gout, arthritis, rheumatoid arthritis, ankylosing spondylitis, Hodgkin's disease, pancreatitis, conjunctivitis, irisitis, scleritis, uveitis, dermatitis (including atopic dermatitis), eczema, multiple sclerosis, etc. Will be included.

또 본 명세서에서 "항산화"란 활성 산소종이 동맥경화, 중풍, 심근 경색, 기미, 주근깨, 잔주름, 암, 백혈병, 교원병(collagen disease)(膠原病, 피부, 관절, 혈관 등 신체의 결합조직에 이상이 생기는 모든 질병), 남성의 생식 기능 저하 등을 일으킨다고 알려져 있는데(Harrison et al, Am J Cardiol, 2003. 2; 91(3A): 7A-11A; Behrend et al, Biochem Soc Trans, 2003. 12; 31: 1441-1444; Agarwal et al, Fertil Steril, 2003. 4; 79(4): 829-843), 이러한 질병들에 대한 개선, 치료, 그러한 질환의 발병 억제 또는 지연을 포함하는 의미이다.In addition, in the present specification, "antioxidant" refers to abnormalities in the connective tissues of the body, such as reactive oxygen species, arteriosclerosis, stroke, myocardial infarction, blemishes, freckles, fine lines, cancer, leukemia, collagen disease (膠原 病, skin, joints, blood vessels) All these diseases), and male reproductive function (Harrison et al, Am J Cardiol, 2003. 2; 91 (3A): 7A-11A; Behrend et al, Biochem Soc Trans, 12 Dec. 2003). 31: 1441-1444; Agarwal et al, Fertil Steril, April 4, 2003; 79 (4): 829-843), including the improvement, treatment, inhibition or delay of the onset of such diseases.

한편 본 발명의 조성물(즉 항염증제 조성물 및 항산화제 조성물; 이하 같음)은 그 유효성분을 용도, 제형, 배합 목적 등에 따라 치료를 의도하는 질환의 개선 활성을 나타낼 수 있는 한 임의의 양(유효량)으로 포함할 수 있는데, 통상적인 유효량은 조성물 전체 중량을 기준으로 할 때 0.001 중량 % 내지 15 중량 % 범위 내에서 결정될 것이다. 여기서 "유효량"이란 그 적용 대상인 포유동물 바람직하게는 사람에게서, 치료를 의도하는 질환의 개선, 치료, 또는 이러한 병리적 증상의 발병 억제/지연을 유도할 수 있는 유효성분의 양을 말한다. 이러한 유효량은 당업자의 통상의 능력 범위 내에서 실험적으로 결정될 수 있다.Meanwhile, the composition of the present invention (that is, the anti-inflammatory composition and the antioxidant composition; the same as below) may be used in any amount (an effective amount) as long as the active ingredient can exhibit the improvement activity of the disease intended to be treated according to the use, formulation, formulation purpose, and the like. Typical effective amounts will be determined within the range of 0.001% to 15% by weight based on the total weight of the composition. The term “effective amount” herein refers to an amount of an active ingredient in a mammal, preferably a human subject to which it is applied, which can induce improvement, treatment, or suppression / delay of the development of such a pathological condition. Such effective amounts can be determined experimentally within the range of ordinary skill in the art.

본 발명의 조성물이 적용(처방)될 수 있는 대상은 포유동물 및 사람이며, 특히 사람인 경우가 바람직하다.Subjects to which the compositions of the invention can be applied (prescribed) are mammals and humans, in particular humans.

본 발명의 조성물은 구체적인 양태에 있어서는 약제학적 조성물로 이용될 수 있다.The composition of the present invention can be used as a pharmaceutical composition in a specific embodiment.

본 발명의 약제학적 조성물은 그 유효성분을 포함하는 이외에 약제학적으로 허용되는 담체, 부형제 등을 포함하여, 경구용 제형(정제, 현탁액, 과립, 에멀젼, 캡슐, 시럽 등), 비경구형 제형(멸균 주사용 수성 또는 유성 현탁액), 국소형 제형(용액, 크림, 연고, 겔, 로션, 패치) 등으로 제조될 수 있다.The pharmaceutical composition of the present invention includes oral formulations (tablets, suspensions, granules, emulsions, capsules, syrups, etc.), parenteral formulations (sterilized), including pharmaceutically acceptable carriers, excipients, etc., in addition to the active ingredients thereof. Aqueous or oily suspensions for injection), topical formulations (solutions, creams, ointments, gels, lotions, patches) and the like.

상기에서 "약제학적으로 허용되는" 의미는 유효성분의 활성을 억제하지 않으면서 적용(처방) 대상이 적응가능한 이상의 독성(충분히 낮은 독성)을 지니지 않는다 의미이다.As used herein, "pharmaceutically acceptable" means that the subject of application (prescription) does not have more toxicity (adequately low toxicity) to which the subject of application (prescription) is adaptable without inhibiting the activity of the active ingredient.

약제학적으로 허용되는 담체의 예로서는 락토스, 글루코스, 슈크로스, 전분(예컨대 옥수수 전분, 감자 전분 등), 셀룰로오스, 그것의 유도체(예컨대 나트륨 카르복시메틸 셀룰로오스, 에틸셀룰로오스, 등) 맥아, 젤라틴, 탈크, 고체 윤활제(예컨대 스테아르산, 스테아르산 마그네슘 등), 황산 칼슘, 식물성 기름(예컨대 땅콩 기름, 면실유, 참기름, 올리브유 등), 폴리올(예컨대 프로필렌 글리콜, 글리세린 등), 알긴산, 유화제(예컨대 TWEENS), 습윤제(예컨대 라우릴 황산 나트륨), 착색제, 풍미제, 정제화제, 안정화제, 항산화제, 보존제, 물, 식염수, 인산염 완충 용액 등을 들 수 있다. 이러한 담체는 본 발명의 약제학적 조성물의 제형에 따라 적당한 것을 하나 이상 선택하여 사용할 수 있다.Examples of pharmaceutically acceptable carriers include lactose, glucose, sucrose, starch (such as corn starch, potato starch, etc.), cellulose, derivatives thereof (such as sodium carboxymethyl cellulose, ethylcellulose, etc.) malt, gelatin, talc, solids Lubricants (e.g. stearic acid, magnesium stearate, etc.), calcium sulfate, vegetable oils (e.g. peanut oil, cottonseed oil, sesame oil, olive oil, etc.), polyols (e.g. propylene glycol, glycerin, etc.), alginic acid, emulsifiers (e.g. TWEENS), wetting agents (e.g. Sodium lauryl sulfate), colorants, flavoring agents, tableting agents, stabilizers, antioxidants, preservatives, water, saline, phosphate buffer solutions and the like. The carrier may be selected from one or more of suitable pharmaceutical formulations according to the formulation of the pharmaceutical composition of the present invention.

부형제도 본 발명의 약제학적 조성물의 제형에 따라 적합한 것을 선택하여 사용할 수 있는데, 예컨대 본 발명의 약제학적 조성물이 수성 현탁제로 제조될 경우에 적합한 부형제로서는 나트륨 카르복시메틸 셀룰로오스, 메틸 셀룰로오스, 히드로프로필메틸셀룰로오스, 알긴산 나트륨, 폴리비닐피롤리돈 등의 현탁제나 분산제 등을 들 수 있다. 주사액으로 제조되는 경우 적합한 부형제로서는 링거액, 등장 염화나트륨 등을 들 수 있다.Excipients may be selected and used according to the formulation of the pharmaceutical composition of the present invention, for example, when the pharmaceutical composition of the present invention is prepared with an aqueous suspending agent, suitable excipients are sodium carboxymethyl cellulose, methyl cellulose, hydropropylmethylcellulose And suspending agents and dispersing agents such as sodium alginate and polyvinylpyrrolidone. Suitable excipients when prepared from injection solutions include Ringer's solution, isotonic sodium chloride, and the like.

본 발명의 약제학적 조성물은 경구 또는 비경구로 투여될 수 있고, 아토피성 피부염 조성물처럼 경우에 따라서는 국소적으로 투여될 수 있다.The pharmaceutical compositions of the present invention may be administered orally or parenterally, and may optionally be administered topically, as in the case of atopic dermatitis compositions.

본 발명의 약제학적 조성물은 그 1일 투여량이 통상 0.001 ~ 150 mg/kg 체중 범위이고, 1회 또는 수회로 나누어 투여할 수 있다. 그러나, 본 발명의 약제학적 조성물의 투여량은 투여 경로, 환자의 연령, 성별, 체중, 환자의 중증도 등의 여러 관련 인자에 비추어 결정되는 것이므로 상기 투여량은 어떠한 측면으로든 본 발명의 범위를 제한하는 것으로 이해되어서는 아니 된다. The daily dose of the pharmaceutical composition of the present invention is usually 0.001 to 150 mg / kg body weight, and may be administered once or several times. However, since the dosage of the pharmaceutical composition of the present invention is determined in view of various related factors such as the route of administration, the age, sex, weight of the patient, the severity of the patient and the like, the dosage may limit the scope of the present invention in any aspect. It should not be understood as.

본 발명의 조성물은 다른 구체적인 양태에 있어서, 식품 조성물로서 파악할 수 있다.The composition of this invention can be grasped | ascertained as a food composition in another specific aspect.

본 발명의 식품 조성물은 건강 보조식품, 특수 영양 보충용 식품, 기능성 음료 등으로 제조될 수 있다.The food composition of the present invention may be prepared as a dietary supplement, a special nutritional supplement, a functional beverage, and the like.

본 발명의 식품 조성물에는 그 유효성분이 포함되는 것 이외에, 옥수수 시럽 고형물, 꿀, 수크로오스, 프룩토오스, 락토오스, 말토오스 등의 감미제, 사과, 레몬, 감귤 등의 과일이나 녹차잎, 둥굴레, 대잎 등의 차류에서 얻어진 풍미제, 카테킨, 레티놀, 아스코르브산, 토코페롤 등의 생리활성 성분, 칼슘, 마그네슘, 크롬, 코발트, 구리, 불소화물 등의 미네랄 등이 또한 첨가될 수 있다.The food composition of the present invention includes not only the active ingredient, but also sweeteners such as corn syrup solids, honey, sucrose, fructose, lactose and maltose, fruits such as apples, lemons and citrus fruits, green tea leaves, round stalks, and large leaves. Flavoring agents obtained from tea, catechins, retinol, ascorbic acid, tocopherol and other biologically active ingredients, calcium, magnesium, chromium, cobalt, copper, fluoride and the like may also be added.

또한 향미나 기호성을 향상시키고 다른 기능성(예컨대 관절염 또는 골다공증 예방)을 추가하기 위하여 한약재가 추가될 수 있는데, 추가될 수 있는 한약재로서는 두충 추출물, 속단 추출물, 녹용 추출물, 홍화인 추출물, 토사자 추출물, 숙지황 추출물, 별갑 추출물, 산수유 추출물, 구기자 추출물, 감초 추출물, 당귀 추출물, 갈근 추출물, 강진향 추출물, 합환피 추출물, 산두근 추출물, 괴화 추출물, 고삼 추출물 등이 예시될 수 있다.In addition, herbal medicines may be added to enhance flavor and palatability and to add other functionalities (such as preventing arthritis or osteoporosis). Extracts, tortoiseshell extracts, cornus extracts, goji berry extract, licorice extract, donkey extract, brown root extract, kangjinhyang extract, haphwanpi extract, mountain rump extract, lump extract, ginseng extract and the like can be exemplified.

본 발명의 조성물은 다른 구체적인 양태에 있어서, 화장품 조성물로 파악할 수 있다.The composition of this invention can be grasped | ascertained as a cosmetic composition in another specific aspect.

본 발명의 화장품 조성물은 그 유효성분을 포함하는 이외에 화장품 제제에 있어서 수용가능한 담체를 포함할 수 있다. The cosmetic composition of the present invention may include an acceptable carrier in the cosmetic formulation in addition to including the active ingredient.

여기서 "화장품 제제에 있어서 수용가능한 담체"란 화장품 제제에 포함될 수 있는 이미 공지되어 사용되고 있는 화합물 또는 조성물이거나 앞으로 개발될 화합물 또는 조성물로서 피부와의 접촉시 인체가 적응 가능한 이상의 독성을 지니지 않는 것을 말한다.Herein, "acceptable carrier in cosmetic preparation" means a compound or composition already known and used that can be included in cosmetic preparations or a compound or composition which will be developed in the future and does not have more toxicity than the body can adapt to when contacted with the skin.

상기 담체는 본 발명의 화장품 조성물에 그것의 전체 중량에 대하여 약 1 중량 % 내지 약 99.99 중량 %, 바람직하게는 조성물의 중량의 약 50 중량% 내지 약 99 중량 %로 포함될 수 있다. The carrier may be included in the cosmetic composition of the present invention in an amount from about 1% to about 99.99% by weight, preferably from about 50% to about 99% by weight of the composition.

그러나 상기 비율은 화장품의 전술한 바의 제형에 따라 또 그것의 구체적인 적용 부위(얼굴이나 손)나 그것의 바람직한 적용량 등에 따라 달라지는 것이기 때문에, 상기 비율은 어떠한 측면으로든 본 발명의 범위를 제한하는 것으로 이해되어서는 안 된다. However, it is understood that the ratios limit the scope of the present invention in any aspect because the ratios vary depending on the formulation of the cosmetics as described above and their specific application site (face or hand) or their preferred application amount. It should not be.

한편, 상기 담체로서는 알코올, 오일, 계면활성제, 지방산, 실리콘 오일, 습윤제, 보습제, 점성 변형제, 유제, 안정제, 자외선 차단제, 발색제, 향료 등이 예시될 수 있다. Meanwhile, examples of the carrier include alcohols, oils, surfactants, fatty acids, silicone oils, wetting agents, moisturizers, viscosity modifiers, emulsions, stabilizers, sunscreen agents, colorants, fragrances, and the like.

상기 담체로서 사용될 수 있는 알코올, 오일, 계면활성제, 지방산, 실리콘 오일, 습윤제, 보습제, 점성 변형제, 유제, 안정제, 자외선 차단제, 발색제, 향료 로 사용될 수 있는 화합물/조성물 등은 이미 당업계에 공지되어 있기 때문에 당업자라면 적절한 해당 물질/조성물을 선택하여 사용할 수 있다.
Alcohols, oils, surfactants, fatty acids, silicone oils, wetting agents, humectants, viscosity modifiers, emulsions, stabilizers, sunscreens, colorants, compounds / compositions that can be used as fragrances, etc., which can be used as the carrier are already known in the art. As a result, those skilled in the art can select and use appropriate materials / compositions.

전술한 바와 같이, 본 발명에 따르면 곽향 정유 추출물을 이용한 항염증제 조성물 및 항산화제 조성물을 제공할 수 있다.As described above, according to the present invention can provide an anti-inflammatory composition and antioxidant composition using the essential oil extract.

본 발명의 항염증제 조성물 및 항산화제 조성물은 약품, 식품, 화장품 등으로 제품화될 수 있다.
The anti-inflammatory composition and the antioxidant composition of the present invention can be commercialized in medicine, food, cosmetics and the like.

도 1 및 도 2는 각각 곽향 정유 추출물(A)이 염증성 사이토카인인 TNF-α 및 IL-8의 생성을 억제함을 보여주는 결과이다.
도 3은 곽향 정유 추출물(A)이 DPPH 라디칼 소거 활성을 보여주는 결과이다.1 and 2 show that the essential oil extract (A) inhibits the production of inflammatory cytokines TNF-α and IL-8, respectively.
Figure 3 is a result showing the essential oil extract (A) extract DPPH radical scavenging activity.

이하 본 발명을 실시예 및 실험예를 사용하여 설명한다. 그러나 본 발명의 범위가 이러한 실시예 및 실험예에 한정되는 것은 아니다.Hereinafter, the present invention will be described using examples and experimental examples. However, the scope of the present invention is not limited to these examples and experimental examples.

<< 실시예Example > > 곽향Kwak Hyang 정유 추출물의 제조 Preparation of Essential Oil Extract

곽향 전초 세절물 200g을 2,000㎖의 플라스크에 넣고 증류수를 1,400㎖를 넣은 후 정유 추출 장치(Karlsruker's apparatus)를 이용하여 휘발 성분을 수집하여 곽향 정유 추출물을 제조하였다.After putting 200 g of Kwakje outpost fines into a 2,000 ml flask, 1,400 mL of distilled water was added, and volatile components were collected using an essential oil extracting device (Karlsruker's apparatus) to prepare a Kwak Hyang essential oil extract.

<< 실험예Experimental Example > > 항염증 활성 및 항산화 활성 실험Anti-inflammatory and Antioxidant Activity Experiment

<실험예 1> 항염증 활성 실험 Experimental Example 1 Anti-inflammatory Activity Experiment

대식세포 계열 (Human monocyte cell line)인 THP-1은 한국세포주은행 (KCLB; Seoul, Korea)으로부터 분양 받아 penicillin-streptomycin 100 units/mL과 10% fetal bovine serum (FBS)이 함유된 RPMI1640 배지 (GIBCO, Grand Island, NY, USA)를 사용하여 37℃, 5% CO2항온기에서 배양하였으며, 3일에 한 번씩 계대배양을 시행하였다. THP-1, a human monocyte cell line, was distributed from Korea Cell Line Bank (KCLB; Seoul, Korea) and contained RPMI1640 medium (GIBCO) containing 100 units / mL of penicillin-streptomycin and 10% fetal bovine serum (FBS). , Grand Island, NY, USA) was used to incubate at 37 ℃, 5% CO 2 incubator, subcultured once every three days.

24 well plate에서 1x105 cell/mL의 THP-1 cell을 FBS를 포함하지 않는 RPMI1640 배지에서 18시간 배양 후, LPS (1μg/mL)를 처리하여 cytokine 생성을 자극하고 동시에 시료를 농도별로 처리하였다. 24시간 동안 동일 조건에서 배양한 다음 세포를 제거하고 상등액 중의 cytokine TNF-α 및 IL-8 양을 ELISA 방법을 이용하여 정량하였다. After incubating 1 × 10 5 cells / mL of THP-1 cells in a 24 well plate for 18 hours in RPMI1640 medium without FBS, LPS (1μg / mL) was treated to stimulate cytokine production and the samples were treated at the same time. After culturing at the same conditions for 24 hours, cells were removed, and the amount of cytokine TNF-α and IL-8 in the supernatant was quantified using the ELISA method.

결과를 [도 1] 및 [도 2]에 나타내었다. [도 1] 및 [도 2]를 참조하여 보면 대체로 상기 곽향 정유 추출물(A)은 농도 의존적으로 염증성 사이토카인인 TNF-α 및 IL-8의 생성을 억제함을 알 수 있다.The results are shown in [FIG. 1] and [FIG. 2]. Referring to FIGS. 1 and 2, it can be seen that the Bakyang essential oil extract (A) generally inhibits the production of inflammatory cytokines TNF-α and IL-8 in a concentration-dependent manner.

<실험예 2> 세포 독성 실험 Experimental Example 2 Cytotoxicity Experiment

대식세포 계열 (Human monocyte cell line)인 THP-1 세포에 대한 세포독성 평가는 MTT 분석 방법으로 실시하였다. MTT (3-(4,5-dimethylthiazol-2-yl)- 2,5-diphenyl-tetrazolium bromide) 는 살아있는 세포에는 formazan 형성을 하지 않는다. Cytotoxicity evaluation of THP-1 cells, a human monocyte cell line, was performed by MTT assay. MTT (3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyl-tetrazolium bromide) does not form formazan in living cells.

24-well plate에 1x105 cell/mL 의 THP-1 세포를 24시간 배양 후, 시료를 농도별로 처리하였다. 배양 후 MTT 시약을 처리하여 3시간 동안 배양하고 DMSO (dimethylsulfoxide) 처리하여 formazan을 녹인 후. ELISA reader로 570nm에서 흡광도를 측정하여 세포독성을 확인하였다.After 24-hour incubation of 1 × 10 5 cells / mL of THP-1 cells in a 24-well plate, samples were treated by concentration. After incubation, incubated for 3 hours by treatment with MTT reagent, and then dissolved formazan by treatment with DMSO (dimethylsulfoxide) . The cytotoxicity was confirmed by measuring the absorbance at 570 nm with an ELISA reader.

결과를 [도 1] 및 [도 2]에 함께 나타내었다. [도 1] 및 [도 2]를 참조하여 보면, 상기 곽향 정유 추출물(A)은 대체로 세포 독성을 보이지 않는데, 이는 곽향 정유 추출물(A)의 상기 염증성 사이토카인의 생성 억제 활성이 세포 독성에 의한 것이 아님을 보여주는 것이라 할 수 있다. The results are shown together in FIGS. 1 and 2. Referring to Figures 1 and 2, the essential oil extract (A) is not generally cytotoxic, which is caused by cytotoxicity of the inhibitory activity of the inflammatory cytokine production of the essential oil extract (A) It can be said that it is not.

<실험예 3> 항산화 활성 실험 Experimental Example 3 Antioxidant Activity

DPPH 라디칼 소거 활성은 Brand-Williams 등의 방법(Brand-Williams et al., Use of a free radical method to evaluate antioxidant activity. Food Sci. Technol. 28(1): 25-30, (1995))에 따라, 여러 농도의 시료에 동량의 0.4mM DPPH 용액을 첨가하여 실온에서 10분간 방치한 후 517nM에서 흡광도를 측정하여 평가하였다.DPPH radical scavenging activity was determined according to Brand-Williams et al. (Brand-Williams et al., Use of a free radical method to evaluate antioxidant activity.Food Sci. Technol. 28 (1): 25-30, (1995)). The same amount of 0.4mM DPPH solution was added to samples of various concentrations, and the resultant was allowed to stand at room temperature for 10 minutes and the absorbance was measured at 517 nM.

DPPH 라디칼 소거 활성을 대조군(무처리군)에 대한 백분율로 [도 3]에 나타내었다(IC50(50% DPPH 라디칼 소거능을 가지는 농도)는 11.2㎕/㎖임). [도 3]를 참조하여 보면 곽향 정유 추출물(A)이 농도 의존적으로 DPPH 라디칼 소거 활성을 가짐을 알 수 있다.
DPPH radical scavenging activity is shown in FIG. 3 as a percentage of the control (untreated group) (IC 50 (concentration with 50% DPPH radical scavenging capacity) is 11.2 μl / ml). Referring to [FIG. 3], it can be seen that the essential oil extract (A) has a DPPH radical scavenging activity in a concentration-dependent manner.

Claims (5)

곽향 정유 추출물을 유효성분으로 포함하는 항염증제 조성물.
Anti-inflammatory composition comprising the extract of Kwak Hyang essential oil as an active ingredient.
곽항 정유 추출물을 유효성분으로 포함하는 항산화제 조성물.
Antioxidant composition comprising Kwakhang essential oil extract as an active ingredient.
제1항 또는 제2항에 있어서,
상기 조성물은 약제학적 조성물인 것을 특징으로 하는 조성물.
The method according to claim 1 or 2,
Wherein said composition is a pharmaceutical composition.
제1항 또는 제2항에 있어서,
상기 조성물은 식품 조성물인 것을 특징으로 하는 조성물.
The method according to claim 1 or 2,
The composition is a composition, characterized in that the food composition.
제1항 또는 제2항에 있어서,
상기 조성물은 화장품 조성물인 것을 특징으로 하는 조성물.

The method according to claim 1 or 2,
The composition is a composition, characterized in that the cosmetic composition.

KR1020100139290A 2010-12-30 2010-12-30 Anti-inflammatory composition and anti-oxidative composition using an extract of teucrium veronicoides KR20120077357A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020100139290A KR20120077357A (en) 2010-12-30 2010-12-30 Anti-inflammatory composition and anti-oxidative composition using an extract of teucrium veronicoides

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020100139290A KR20120077357A (en) 2010-12-30 2010-12-30 Anti-inflammatory composition and anti-oxidative composition using an extract of teucrium veronicoides

Publications (1)

Publication Number Publication Date
KR20120077357A true KR20120077357A (en) 2012-07-10

Family

ID=46710859

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020100139290A KR20120077357A (en) 2010-12-30 2010-12-30 Anti-inflammatory composition and anti-oxidative composition using an extract of teucrium veronicoides

Country Status (1)

Country Link
KR (1) KR20120077357A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016190546A1 (en) * 2015-05-22 2016-12-01 성균관대학교 산학협력단 Composition for preventing or treating liver disease comprising pogostemonis herba extract
KR20180100839A (en) * 2017-03-02 2018-09-12 주식회사 뉴트리사이언스 A composition comprising heat water extract of gojiberry, fig, and agastache rugosa as active ingredients
US10682384B2 (en) 2017-02-28 2020-06-16 Cosmax Ns, Inc. Composition comprising natural complex extract as active ingredient
KR20220052770A (en) * 2020-10-21 2022-04-28 코스맥스 주식회사 Cosmetic composition for improving skin conditions comprising protein hydrolysate of Agastache rugosa

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016190546A1 (en) * 2015-05-22 2016-12-01 성균관대학교 산학협력단 Composition for preventing or treating liver disease comprising pogostemonis herba extract
US10682384B2 (en) 2017-02-28 2020-06-16 Cosmax Ns, Inc. Composition comprising natural complex extract as active ingredient
KR20180100839A (en) * 2017-03-02 2018-09-12 주식회사 뉴트리사이언스 A composition comprising heat water extract of gojiberry, fig, and agastache rugosa as active ingredients
KR20220052770A (en) * 2020-10-21 2022-04-28 코스맥스 주식회사 Cosmetic composition for improving skin conditions comprising protein hydrolysate of Agastache rugosa

Similar Documents

Publication Publication Date Title
KR101110064B1 (en) Anti-inflammatory Composition
MX2007005886A (en) Pharmaceutical and therapeutic compositions derived from garcinia mangostana l plant.
KR20130060611A (en) Anti-inflammatory composition using a flower extract of citrus unshiu
KR101136742B1 (en) Extract of Soft Corals and Use Thereof
US7511078B2 (en) Antiallergic agents, drugs, foods, drinks or cosmetics containing them and process for producing the same
KR20120077357A (en) Anti-inflammatory composition and anti-oxidative composition using an extract of teucrium veronicoides
KR101616011B1 (en) Composition for Anti-imflammation Using an Extract of Immature Fruits of Litsea japonica or Compounds Isolated Therefrom
JP2013151451A (en) Antioxidation/antiallergic agent containing extract of impatiens
KR101455842B1 (en) Anti-Inflammation Composition and an Improvment Composition of Atopic Dermatitis Using an Extract of Immature Fruit of Diospyros kaki
KR101223749B1 (en) Composition for Improving Atopy Dermatitis Using a Extract of Humulus japonicus or a Extract of Quercus acuta
JP4169244B2 (en) Antiallergic agent and method for producing the same
KR101033921B1 (en) Composition for reducing irritation and inflammation in skin
KR20120100859A (en) Anti-inflammatory composition using a extract of ficus erecta leaf
KR102605627B1 (en) Leucine derivatives, composition comprising the same, and uses thereof
JP4672269B2 (en) Anti-aging agent, platelet aggregation inhibitor, antioxidant, antiallergic agent, skin cosmetics and food and drink
KR20210066089A (en) Composition for Anti-inflammation Using an Extract of Lemon Peel and a Root Extract of Sophora flavescens
WO2015186962A1 (en) Composition for alleviating atopic dermatitis, using fermented green tea extract
KR101141182B1 (en) Composition for Anti-inflammation
KR20160080513A (en) Anti-inflammation Composition Using Extracts of Zizania latifolia
KR101490512B1 (en) Anti-Inflammation Composition and an Improvment Composition of Atopic Dermatitis Using an Extract of Immature Fruit of Diospyros kaki
JP2009161526A (en) Treating agent
KR101491705B1 (en) Anti-inflammation Composition Using Acrosorium yendoi Extracts
KR101576337B1 (en) Composition for prevention or improving of inflammatory skin disease, or anti-oxidation comprising Zea mays leaves extract
KR20110137047A (en) Anti-inflammation composition using an extract of hypochoeris radicata
KR20130009238A (en) Composition for improving skin diseases

Legal Events

Date Code Title Description
WITN Withdrawal due to no request for examination